The Civic Node

The DEA's Manufactured Crisis

4 min read

Summary

Personal essay in ADDitude Magazine (the leading ADHD publication) by Dr. William Dodson, a fellow of the American Psychiatric Association. Argues that the DEA — not pharmaceutical companies, raw material shortages, or telehealth providers — is solely responsible for the ongoing ADHD stimulant medication shortage through its rigid quota system. Makes the case that the FTC’s public inquiry was designed to find cover for the DEA rather than fix the actual problem.

Key Points

  • DEA is the only government agency that sets production and distribution quotas for Schedule II controlled substances. It decides how much medication can be released to pharmacies each month.
  • The quota system requires predicting demand 21 months in advance (determined in March/April for the following calendar year); this inflexibility is the structural root of the shortage.
  • DEA’s 2022 decision: concluded that ADHD stimulants were being diverted/abused at scale despite “virtually no evidence.” About 90% of diverted immediate-release stimulants are used by a narrow demographic: white male college students to stay awake, not people with ADHD.
  • Online-only telehealth prescribers (the DEA’s stated target) never accounted for more than 1% of all prescriptions; these “bad actors” closed down 2+ years before the article was written, yet the shortage continues.
  • The growth in ADHD medication demand is driven by late-diagnosed adults — a legitimate clinical population. “The relative number of children and adolescents taking stimulants has not changed in 20 years.”
  • Drug companies were making and distributing as much as the DEA’s quotas allowed — they cannot increase production above the cap.
  • Dodson suspects the FTC’s public inquiry (inviting comment on stimulant shortage) was designed to place blame elsewhere rather than on the DEA.
  • Even if the DEA decided to raise quotas in April, its distribution mechanism couldn’t allow an increase until January of the following year.

Newsletter Angles

  • The bureaucratic self-protection mechanism: the DEA created the shortage, refuses to acknowledge it, and other agencies (FTC, FDA) are now helping obscure the cause. Classic institutional blame diffusion.
  • The human cost of regulatory rigidity: people with ADHD who describe stimulants as “a lifeline for daily functioning” are being forced to navigate a monthly bureaucratic obstacle course — using the very executive function they lack without medication — to obtain it.
  • The demographic irony: DEA justified the crackdown on fears of abuse by white male college students (who represent actual diverted use), but the shortage falls heaviest on the legitimate ADHD population who depend on the medication to function.

Entities Mentioned

  • DEA — Drug Enforcement Administration; root cause of the shortage per Dodson
  • FTC — Federal Trade Commission; argued to be providing political cover for DEA
  • FDA — also implicated in blame diffusion
  • American Psychological Association — Dodson’s professional body (Fellow)

Concepts Mentioned

Quotes

“The DEA does not bother with facts. Its answer to this increased level of prescriptions: Decrease the amount of drug available regardless of consequences.”

“The time has long since passed for the DEA to admit its fault and fix its broken quota system. There has already been too much needless suffering by innocent people who did nothing to cause the DEA’s restrictions.”

Notes

This is a clearly positioned opinion essay (ADDitude itself notes it “reflects the opinions of the author”). Dodson is a credentialed psychiatrist with ADHD specialty, but the piece is advocacy, not peer-reviewed research. The core structural claim (DEA quotas as the mechanism) is factually accurate and well-documented elsewhere; the political claim (FTC providing cover for DEA) is Dodson’s interpretation. Worth cross-referencing with FDA and DEA statements.

Graph View

Backlinks